INFLUENZA CVD 15000: EVALUATION OF A BOOSTER DOSE OF A/VIETNAM/1203/04 (H5N1)

流感 CVD 15000：A/VIETNAM/1203/04 (H5N1) 加强剂量的评估

• 批准号: 7608155
• 负责人: JAMES D CAMPBELL
• 金额: $ 3.37万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2008-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608155
• 关键词: Avian Influenza; Avian Influenza A Virus; Bird Flu vaccine; Computer Retrieval of Information on Scientific Projects Database; Dose; Evaluation; Funding; Grant; Influenza; Influenza A Virus, H5N1 Subtype; Institution; Research; Research Personnel; Resources; Source; Testing; United States; United States Food and Drug Administration; United States National Institutes of Health; Vaccines; Vietnam; influenza virus vaccine; research study; volunteer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Volunteers previously took part in a research study to test an experimental vaccine against the A/H5N1 bird flu virus and are now being asked if they would like to take part in an extension study. As part of the original study, they received two doses of the A/H5N1 bird flu vaccine.In the new study volunteers will receive a third dose (booster) at the same dose level as the original study.The vaccine, which is made by sanofi pasteur, Inc. (previously known as Aventis Pasteur, Inc.), is made the same way that the "regular flu" vaccine is made. The A/H5N1 bird flu vaccine is not yet approved by the Food and Drug Administration for use in the United States.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 志愿者此前曾参加过一项研究，以测试针对A/H5N1鸟类流感病毒的实验疫苗，现在被问及他们是否想参加扩展研究。作为原始研究的一部分，他们收到了两剂A/H5N1鸟流感疫苗。在新的研究志愿者中将以与原始研究相同的剂量水平获得第三剂（增强剂）。该疫苗是由Sanofi Pasteur，Inc。（以前称为Aventis Pasteur，Inc.）制造的，是与“常规流感”的相同方式。 A/H5N1鸟流感疫苗尚未获得美国食品药品监督管理局在美国使用的批准。